Opendata, web and dolomites

ELBA SIGNED

European Liquid Biopsies Academy - Towards widespread clinical application of blood- based diagnostic tools

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ELBA project word cloud

Explore the words cloud of the ELBA project. It provides you a very rough idea of what is the project "ELBA" about.

designed    inclusion    biopsies    property    generation    15    statistical    elba    detected    excellent    regulatory    therapy    sensitive    chain    curriculum    commercialisation    communication    career    obstacles    multidisciplinary    clinic    innovative    game    medical    materialised    bioinformatical    clinical    creative    minimally    educational    hampering    network    mindset    bioinformatics    invasive    disciplines    tissue    deployment    affairs    health    transferable    biopsy    skills    balanced    expertise    entire    diagnostics    changer    safe    sustainable    economics    subtypes    toolbox    tools    despite    technologies    patient    translation    training    integrate    stakeholders    promise    individual    cover    accelerate    tests    stage    educate    liquid    classified    molecular    alternative    cancer    blood    source    proficiency    heralded    cancers    infancy    diagnostic    complimentary    academy    solid    networks    matched    biostatistics    mathematical    intellectual    move    sectors    leadership    esrs    relationships    circumvent   

Project "ELBA" data sheet

The following table provides information about the project.

Coordinator
STICHTING VUMC 

Organization address
address: DE BOELELAAN 1117
city: AMSTERDAM
postcode: 1081 HV
website: www.vumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 3˙727˙722 €
 EC max contribution 3˙727˙722 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VUMC NL (AMSTERDAM) coordinator 510˙748.00
2    CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER FR (MONTPELLIER) participant 525˙751.00
3    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 498˙432.00
4    INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL ES (BADALONA BARCELONA) participant 495˙745.00
5    UNIVERSIDAD DE GRANADA ES (GRANADA) participant 495˙745.00
6    FUNDACAO D. ANNA SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD PT (LISBOA) participant 476˙712.00
7    EXOSOMICS SIENA SPA IT (SIENA) participant 258˙061.00
8    PANGAEA BIOTECH SL ES (BARCELONA) participant 247˙872.00
9    PLOVDIVSKI UNIVERSITET PAISIY HILENDARSKI BG (PLOVDIV) participant 218˙651.00
10    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) partner 0.00
11    Factory-CRO BV NL (Bilthoven) partner 0.00
12    GenomeScan B.V. NL (Leiden) partner 0.00
13    GILUPI GMBH DE (POSTDAM) partner 0.00
14    IZON SCIENCE LIMITED UK (OXFORD) partner 0.00
15    Sense About Science UK (London) partner 0.00
16    TATAA BIOCENTER AB SE (GOTEBORG) partner 0.00
17    TTOPSTART BV NL (UTRECHT) partner 0.00
18    UNIVERSITEIT TWENTE NL (ENSCHEDE) partner 0.00
19    University of Padova IT (Padua) partner 0.00
20    University of Szeged US (CAMBRIDGE) partner 0.00
21    V.O. Patents & Trademarks DE (Munich) partner 0.00

Map

 Project objective

Liquid biopsies have been heralded as a game changer in cancer management, with blood tests offering a minimally invasive, safe, and sensitive alternative or complimentary approach for tissue biopsies. Blood represents a rich source of information through which solid cancers (and their subtypes) can be detected, identified and classified, and matched to a specific therapy. However, despite the potential of individual approaches, the promise of liquid biopsies has not yet materialised in the clinic. Widespread deployment requires creative next-generation researchers with an innovative mindset with access to a unique toolbox, including medical know-how, molecular diagnostics expertise (from health economics to regulatory), and statistical/bioinformatical proficiency. Currently, there are no comprehensive training programmes to address this need. To move the promising liquid biopsy technology out of its infancy, the research programme and educational curriculum of the European Liquid Biopsy Academy (ELBA) will cover the entire value chain of diagnostics development and integrate all required disciplines and sectors.

ELBA will educate 15 Early Stage Researchers (ESRs) with the skills to circumvent the obstacles currently hampering effective development and commercialisation of liquid biopsy approaches. By creating a sustainable network to foster long-term multidisciplinary relationships and communication networks with various stakeholders we aim to accelerate clinical translation of these blood-based diagnostics. Most importantly, we have designed a well-balanced training programme to provide excellent career opportunities for the 15 ELBA ESRs. this includes training on state-of-the-art technologies and tools; bioinformatics, biostatistics and mathematical modelling; health economics and health technology assessment; diagnostic test development (including intellectual property and regulatory affairs); transferable skills (including leadership) and patient inclusion.

 Deliverables

List of deliverables.
First online version of network public website Other 2019-06-19 14:53:28
Call for applications Other 2019-06-19 14:53:28

Take a look to the deliverables list in detail:  detailed list of ELBA deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 J W P Bracht, J Berenguer, N Karachaliou, M Filipska, R Rosell
Combining plasma-based biosources to predict treatment response in NSCLC patients
published pages: 2022-2022, ISSN: 0923-7534, DOI: 10.1093/annonc/mdy246
Annals of Oncology 29/9 2019-11-22
2019 Martyna Filipska, Carlos Pedraz-Valdunciel, Imane Chaib, Rafael Rosell
Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy
published pages: 457-467, ISSN: 1471-2598, DOI: 10.1080/14712598.2019.1582635
Expert Opinion on Biological Therapy 19/5 2019-11-22
2019 Niki Karachaliou, Jordi Codony-Servat, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Martyna Filipska, Carlos Pedraz, Imane Chaib, Jordi Bertran-Alamillo, Andres Felipe Cardona, Miguel Angel Molina, Rafael Rosell
Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
published pages: 1019-1028, ISSN: 1747-6348, DOI: 10.1080/17476348.2019.1656068
Expert Review of Respiratory Medicine 13/10 2019-11-22
2019 Ernesto Aparicio-Puerta, Ricardo Lebrón, Antonio Rueda, Cristina Gómez-Martín, Stavros Giannoukakos, David Jaspez, José María Medina, Andreja Zubkovic, Igor Jurak, Bastian Fromm, Juan Antonio Marchal, José Oliver, Michael Hackenberg
sRNAbench and sRNAtoolbox 2019: intuitive fast small RNA profiling and differential expression
published pages: W530-W535, ISSN: 0305-1048, DOI: 10.1093/nar/gkz415
Nucleic Acids Research 47/W1 2019-10-30
2019 Myron G. Best, Sjors G. J. G. In ’t Veld, Nik Sol, Thomas Wurdinger
RNA sequencing and swarm intelligence–enhanced classification algorithm development for blood-based disease diagnostics using spliced blood platelet RNA
published pages: , ISSN: 1754-2189, DOI: 10.1038/s41596-019-0139-5
Nature Protocols 2019-06-19
2018 Ernesto Aparicio-Puerta, David Jáspez, Ricardo Lebrón, Danijela Koppers-Lalic, Juan A Marchal, Michael Hackenberg
liqDB: a small-RNAseq knowledge discovery database for liquid biopsy studies
published pages: D113-D120, ISSN: 0305-1048, DOI: 10.1093/nar/gky981
Nucleic Acids Research 47/D1 2019-06-19
2018 Jillian Wilhelmina Paulina Bracht, Clara Mayo-de-las-Casas, Jordi Berenguer, Niki Karachaliou, Rafael Rosell
The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
published pages: , ISSN: 1523-3790, DOI: 10.1007/s11912-018-0720-z
Current Oncology Reports 20/9 2019-06-19

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ELBA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ELBA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

i-CONN (2019)

Interdisciplinary connectivity: Understanding and managing complex systems using connectivity science

Read More  

MoSaiQC (2020)

Modular Systems for Advanced Integrated Quantum Clocks

Read More  

CHANGE (2019)

Cultural Heritage Analysis for New GEnerations

Read More